Introduction

Dr Jian Guan completed her Bachelor of Medicine in China in 1982. After eight years of practice as a Paediatrician she obtained a PhD. in Paediatrics at the University of Auckland (New Zealand) in 1996. Throughout her career, she has pioneered research in insulin-like growth factor-1 (IGF-1) and its role in brain function.

Currently an Associate Professor affiliated with the Department of Pharmacology and Clinical Pharmacology at the Faculty of Medical and Health Sciences (University of Auckland), Jian is also the Chief Scientist of The cGP Lab Ltd.

In her esteemed career, Jian has published 80 papers (34 of which have been cited >34 times) and has collaborated with the likes of Dr. Peter Gluckman, formerly the Principal Science Adviser to the Prime Minister.

With clinical background, her research has been largely focused on the pharmaceutical and nutraceutical developments of IGF-1derived small peptides for treatment of neurodevelopmental and cerebral vascular diseases. Her most recent work seeks to understand systemic vascular diseases and the potential of alleviating symptoms by improving IGF-1 function.

Her discovery of a missing link of IGF-1 autocrine regulation led to clinical evaluations for developing a novel biomarker for IGF-1 function, including its clinical application for small vessel diseases such as cognitive impairment and metabolic disorders.

A recent discovery of natural cGP from food, led to the development of an oral cGP supplement for improving brain health, cognition and, potentially, metabolic syndrome (cGPMAXTM).

SCROLL

Title

Doluptur, to velit doluptati doluptaspedi nones ea alique volute in cus. Te nobisci licimuscid ut lame quamus earcid quis rerunt poressundit lacessi nveniat.

Neuren Pharmaceuticals, Australia (1997-2007)
As a key scientist Dr Guan played a critical role in research & development in determining the neuroprotective eff ects of IGF-1 metabolite- GPE which ultimately led to the establishment of the fi rst university-based pharmaceutical company in New Zealand (NeuronZ Ltd, est. 1997). This was subsequently privatised in 2007 and is now known as Neuren Pharmaceuticals Ltd.She was contracted out through University of Auckland and working for Neuren Pharmaceuticals to lead a research team for developing several compounds for neurological conditions. One compound has gained FDA-approval for treating a developmental neurological condition, and another compound is undergoing clinical trials. She continued working with Neuren Pharmaceutical to provide consultancy services after resuming her appointment with the University of Auckland until the company moved to overseas

Slide 2
As a key scientist Dr Guan played a critical role in research & development in determining the neuroprotective eff ects of IGF-1 metabolite- GPE which ultimately led to the establishment of the fi rst university-based pharmaceutical company in New Zealand (NeuronZ Ltd, est. 1997). This was subsequently privatised in 2007 and is now known as Neuren Pharmaceuticals Ltd.She was contracted out through University of Auckland and working for Neuren Pharmaceuticals to lead a research team for developing several compounds for neurological conditions. One compound has gained FDA-approval for treating a developmental neurological condition, and another compound is undergoing clinical trials. She continued working with Neuren Pharmaceutical to provide consultancy services after resuming her appointment with the University of Auckland until the company moved to overseas

Slide 3
As a key scientist Dr Guan played a critical role in research & development in determining the neuroprotective eff ects of IGF-1 metabolite- GPE which ultimately led to the establishment of the fi rst university-based pharmaceutical company in New Zealand (NeuronZ Ltd, est. 1997). This was subsequently privatised in 2007 and is now known as Neuren Pharmaceuticals Ltd.She was contracted out through University of Auckland and working for Neuren Pharmaceuticals to lead a research team for developing several compounds for neurological conditions. One compound has gained FDA-approval for treating a developmental neurological condition, and another compound is undergoing clinical trials. She continued working with Neuren Pharmaceutical to provide consultancy services after resuming her appointment with the University of Auckland until the company moved to overseas

Slide 4
As a key scientist Dr Guan played a critical role in research & development in determining the neuroprotective eff ects of IGF-1 metabolite- GPE which ultimately led to the establishment of the fi rst university-based pharmaceutical company in New Zealand (NeuronZ Ltd, est. 1997). This was subsequently privatised in 2007 and is now known as Neuren Pharmaceuticals Ltd.She was contracted out through University of Auckland and working for Neuren Pharmaceuticals to lead a research team for developing several compounds for neurological conditions. One compound has gained FDA-approval for treating a developmental neurological condition, and another compound is undergoing clinical trials. She continued working with Neuren Pharmaceutical to provide consultancy services after resuming her appointment with the University of Auckland until the company moved to overseas

Slide 5
As a key scientist Dr Guan played a critical role in research & development in determining the neuroprotective eff ects of IGF-1 metabolite- GPE which ultimately led to the establishment of the fi rst university-based pharmaceutical company in New Zealand (NeuronZ Ltd, est. 1997). This was subsequently privatised in 2007 and is now known as Neuren Pharmaceuticals Ltd.She was contracted out through University of Auckland and working for Neuren Pharmaceuticals to lead a research team for developing several compounds for neurological conditions. One compound has gained FDA-approval for treating a developmental neurological condition, and another compound is undergoing clinical trials. She continued working with Neuren Pharmaceutical to provide consultancy services after resuming her appointment with the University of Auckland until the company moved to overseas

1997

2000

2008

2011

2023